SEC Filing Summary: Athira Pharma, Inc. (ATHA)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. on November 6, 2025. The filing serves to report the Company's financial results for the quarter ended September 30, 2025. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Bothell, WA. The filing references a press release (Exhibit 99.1) containing the detailed results.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms that results for the quarter ended September 30, 2025, have been issued.
Guidance, Outlook, and Risks
- Disclosure Channels: The Company utilizes its website, investor relations portal, and social media accounts (X, LinkedIn, Instagram, Facebook) to disseminate material information regarding product candidates and other matters.
- Regulation FD: The filing includes a standard Regulation FD disclosure statement, noting that information released through the aforementioned channels may be deemed material.
- Legal Status: The information furnished under Items 2.02 and 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated November 6, 2025), as they are absent from this 8-K summary text.
- Confirm the Company's status as an Emerging Growth Company and any implications for financial reporting standards.
- Review the Company's social media channels and investor relations website for any additional material updates on product candidates mentioned in the filing.
- Note the discrepancy between the request metadata ("Leonabio, Inc.") and the actual filing registrant ("Athira Pharma, Inc.").